HtmlToText
news & media investors english français english about overview management team board of directors scientific advisory board scientific approach product pipeline overview imeglimin - us/eu imeglimin - japan/asia pxl770 publications posters partners contact careers news & media investors experts in metabolic diseases poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, including type 2 diabetes. get to know us targeting mitochondrial dysfunction our lead product, imeglimin, is in phase 3 development in japan and has successfully completed phase 2 development in the u.s. and eu. view candidate innovative pipeline of first-in-class products our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes. view pipeline backed by strong leadership our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline. meet our team latest news jul 18, 2018 poxel announces favorable results for pxl770 phase 1b multiple ascending dose trial and drug-drug interaction study pxl770 observed to have a favorable safety and pharmacokinetic profile in the complete phase 1 program pxl770 is advancing into a phase 2a proof-of-concept program for … read this press release : poxel announces favorable results for pxl770 phase 1b multiple ascending dose trial and drug-drug interaction study jul 10, 2018 poxel announces second quarter and first half 2018 financial update lyon, france--(business wire)-- (euronext – poxel – fr0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including… read this press release : poxel announces second quarter and first half 2018 financial update jul 3, 2018 poxel announces completion of patient enrollment for times 1 trial in the phase 3 registration program for imeglimin, an investigational therapeutic agent for type 2 diabetes, in japan phase 3 times 1 data readout is on track for the second quarter of 2019 japanese new drug application submission for imeglimin targeted in 2020 … read this press release : poxel announces completion of patient enrollment for times 1 trial in the phase 3 registration program for imeglimin, an investigational therapeutic agent for type 2 diabetes, in japan view investor relations contact us © 2018 . all rights reserved. privacy policy disclaimer sitemap
Informations Whois
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
Domain Name: poxel.com
Registry Domain ID: 479915464_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.ovh.com
Registrar URL: http://www.ovh.com
Updated Date: 2016-12-13T08:32:47.0Z
Creation Date: 2006-06-10T11:59:44.0Z
Registrar Registration Expiration Date: 2020-06-10T11:59:44.0Z
Registrar: OVH, SAS
Registrar IANA ID: 433
Registrar Abuse Contact Email: abuse@ovh.net
Registrar Abuse Contact Phone: +33.972101007
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Registry Registrant ID:
Registrant Name: Kuhn Thomas
Registrant Organization:
Registrant Street: 3 chemin du juge de paix
Registrant City: ECULLY
Registrant State/Province:
Registrant Postal Code: 69130
Registrant Country: FR
Registrant Phone: +33.670809029
Registrant Phone Ext:
Registrant Fax:
Registrant Fax Ext:
Registrant Email: thomas.kuhn@poxelpharma.com
Registry Admin ID:
Admin Name: POXEL
Admin Organization: POXEL
Admin Street: 259/261 avenue Jean Jaurès
Admin City: LYON
Admin State/Province:
Admin Postal Code: 69007
Admin Country: FR
Admin Phone: +33.437372010
Admin Phone Ext:
Admin Fax: +33.437708815
Admin Fax Ext:
Admin Email: isabelle.tronel@poxelpharma.com
Registry Tech ID:
Tech Name: POXEL
Tech Organization: POXEL
Tech Street: 259/261 avenue Jean Jaurès
Tech City: LYON
Tech State/Province:
Tech Postal Code: 69007
Tech Country: FR
Tech Phone: +33.437372010
Tech Phone Ext:
Tech Fax: +33.437708815
Tech Fax Ext:
Tech Email: isabelle.tronel@poxelpharma.com
Name Server: dns14.ovh.net
Name Server: ns14.ovh.net
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System:
http://wdprs.internic.net/
>>> Last update of WHOIS database: 2016-12-13T09:33:24.0Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
###############################################################################
#
# Welcome to the OVH WHOIS Server.
#
# whois server : whois.ovh.com check server : check.ovh.com
#
# The data in this Whois is at your disposal with the aim of supplying you the
# information only, that is helping you in the obtaining of the information
# about or related to a domain name registration record. OVH Sas make this
# information available "as is", and do not guarantee its accuracy. By using
# Whois, you agree that you will use these data only for legal purposes and
# that, under no circumstances will you use this data to: (1) Allow, enable,
# or otherwise support the transmission of mass unsolicited, commercial
# advertisement or roughly or requests via the individual mail (courier),
# the E-mail (SPAM), by telephone or by fax. (2) Enable high volume, automated,
# electronic processes that apply to OVH Sas (or its computer systems).
# The copy, the compilation, the re-packaging, the dissemination or the
# other use of the Whois base is expressly forbidden without the prior
# written consent of OVH. Domain ownership disputes should be settled using
# ICANN's Uniform Dispute Resolution Policy: http://www.icann.org/udrp/udrp.htm
# We reserve the right to modify these terms at any time. By submitting
# this query, you agree to abide by these terms. OVH Sas reserves the right
# to terminate your access to the OVH Sas Whois database in its sole
# discretion, including without limitation, for excessive querying of
# the Whois database or for failure to otherwise abide by this policy.
#
# L'outil du Whois est à votre disposition dans le but de vous fournir
# l'information seulement, c'est-à-dire vous aider dans l'obtention de
# l'information sur ou lié à un rapport d'enregistrement de nom de domaine.
# OVH Sas rend cette information disponible "comme est," et ne garanti pas
# son exactitude. En utilisant notre outil Whois, vous reconnaissez que vous
# emploierez ces données seulement pour des buts légaux et ne pas utiliser cet
# outil dans les buts suivant: (1) la transmission de publicité non sollicitée,
# commerciale massive ou en gros ou des sollicitations via courrier individuel,
# le courrier électronique (c'est-à-dire SPAM), par téléphone ou par fax. (2)
# l'utilisation d'un grand volume, automatisé des processus électroniques qui
# soulignent ou chargent ce système de base de données Whois vous fournissant
# cette information. La copie de tout ou partie, la compilation, le
# re-emballage, la dissémination ou d'autre utilisation de la base Whois sont
# expressément interdits sans consentement écrit antérieur de OVH. Un désaccord
# sur la possession d'un nom de domaine peut être résolu en suivant la Uniform
# Dispute Resolution Policy de l'ICANN: http://www.icann.org/udrp/udrp.htm
# Nous nous réservons le droit de modifier ces termes à tout moment. En
# soumettant une requête au Whois vous consentez à vous soumettre à ces termes.
# local time : Saturday, 15-Jul-17 17:49:18 CEST
# gmt time : Saturday, 15-Jul-17 15:49:18 GMT
# last modify : Tuesday, 13-Dec-16 10:33:24 CET
# request from : 192.168.248.111:16446
REGISTRAR OVH
REFERRER http://www.ovh.com
SERVERS
SERVER com.whois-servers.net
ARGS domain =poxel.com
PORT 43
SERVER whois.ovh.com
ARGS poxel.com
PORT 43
TYPE domain
RegrInfo
DOMAIN
NAME poxel.com
NSERVER
DNS14.OVH.NET 213.251.188.133
NS14.OVH.NET 213.251.128.133
STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
CHANGED 2016-12-13
CREATED 2006-06-10
EXPIRES 2020-06-10
REGISTERED yes
Go to top
poxel.com rapport :
Visitez le site